GlycoEra raises €44.1M Series A round
5 November 2021· Wädenswil, Switzerland· health, biotechnology, protein_degradation, glycoengineering, drug_discovery, autoimmune_diseases
To support the growth of the company and to demonstrate the breadth and value of its CustomGlycan Platform technology in developing assets that can unlock unique biological activities for therapeutic targets in several disease indications.
Investors
Lead5AM Ventures
Also participating
Sofinnova PartnersRoche Venture FundLimmaTech Biologics AG
About GlycoEra
Stage
Series B
Headquarters
Wädenswil, Switzerland
Founded
2020
Team Size
21–50
Sectors
healthbiotechnologyprotein_degradationglycoengineeringdrug_discoveryautoimmune_diseases